Sellas Shares Drop 22% After $150 Million Offering Pricing
Sellas Life Sciences Group shares fell 22% to $13.98 in premarket trading Thursday after the biopharmaceutical company priced a public offering intended to raise $150 million. The decline followed a sharp run-up: through Wednesday’s close, the stock had more than quadrupled year to date.
November 19, 2026, 03:52 PM 2,837 0
Sellas said late Wednesday it would sell more than 11.5 million shares of common stock at $13 each. Underwriters also received a 30-day option to buy up to about 1.73 million additional shares at the offering price, less discounts and commissions.
J.P. Morgan and TD Cowen are the lead book-running managers. The offering is expected to close Friday.
Comments (0)
No comments yet. Be the first!